Inventiva S.A. Announces Ordinary and Extraordinary General Meeting

Inventiva S.A., a French biopharmaceutical company, has announced its Ordinary and Extraordinary General Meeting to be held on November 27, 2025, at 9:00 a.m. in Paris, France. The meeting will address several key agenda items, including the approval of the Chief Executive Officer's compensation policy for the 2025 financial year, the approval of a settlement agreement with Mr. Frédéric Cren, and the partial waiver of conditions associated with the grant of free shares to Mr. Cren. Additionally, the meeting will consider authorizations for the Board of Directors to grant share subscription and purchase options to employees and corporate officers, and to increase the company's share capital through the issuance of ordinary shares or securities. The meeting will also delegate powers to carry out necessary formalities. The notice of meeting, including the full agenda and draft resolutions, has been published and is available to shareholders.